Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System

 Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System

Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System

Shots:

  • Medtronic initiates global pivotal study evaluating its EV ICD system to treat dangerously fast heart rhythms in 400 patients at 60 sites across North America, Europe, the Middle East, Asia, Australia and New Zealand with the 1EPs as defibrillation testing success rate at the implant
  • The EV ICD pivotal study follows the chronic EV ICD pilot study, evaluated 21 patients in New Zealand and Australia and early research and acute feasibility studies including the ASD, SPACE & ASD2
  • The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins

Click here to­ read full press release/ article | Ref: Medtronics | Image: Waterfall City

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post